常用抗结核二线药物耐药机制研究进展  

Advances in the mechanisms of resistance to commonly used second-line anti-tuberculosis drugs

作　　者：张冉冉[1] 陈伟伟[1] 曹雯[1] 陈晋[1] 

机构地区：[1]同济大学附属上海市肺科医院检验科,200433

出　　处：《国际呼吸杂志》2017年第17期1344-1348,共5页International Journal of Respiration

摘　　要：结核病（tuberculosis，TB）仍是全球最严重的传染病之一。随着结核分枝杆菌（Mycobacterium tuberculosis，MTB）对一线抗结核药物耐药性增强，二线抗结核药物如氟喹诺酮类、氨基糖苷类和硫代酰胺类等在临床应用中越来越受到重视。近年来MTB对二线药物耐药性不断增加，使得其耐药机制成为诸多学者的研究热点。常见的耐药机制有MTB基因突变导致耐药、细胞壁结构及通透性改变和药物外排泵等，但仍有部分机制不甚清楚。本文就MTB对常用抗结核二线药物的耐药机制进行综述，为改善结核病的治疗提供理论参考。Tuberculosis （TB） is still one of the most serious infectious diseases in the world. With the increase of Mycohacterium tuberculosis （MTB） resistance to first-line anti-TB drugs, second-line anti- TB drugs such as fluoroquinolones, aminoglycosides and thioamides are given more and more attention in clinical applications. As the increase of MTB resistance to second-line drugs, the mechanism of resistance to second-line anti-TB drugs has become a hotspot for many scholars. There are some common resistant mechanisms such as drug resistance by gene mutations, changes in cell wall structure and permeability and drug efflux pump and other mechanisms, but there are still some mechanisms unclear. This review summarized the mechanism of MTB resistance to commonly used second-line anti-TB drugs which orovides theoretical references for improving the treatment of Tuberculosis.

关 键 词：结核分枝杆菌 二线抗结核药物 耐药机制 

分 类 号：R446.5[医药卫生—诊断学] R52[医药卫生—临床医学]